Miriam Merad, M.D.; Ph.D. is the Dean of Translational Research and Therapeutic Innovation, Chair of the Department of Immunology and Immunotherapy, Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC).

She is an internationally acclaimed physician-scientist and a leader in the fields of dendritic cell and macrophage biology with a focus on their contribution to Human diseases. Dr. Merad identified the tissue-resident macrophage lineage and revealed its distinct role in organ physiology and pathophysiology. She established the contribution of this macrophage lineage to cancer progression and inflammatory diseases and is now working on developing novel macrophage-targeted therapies for these conditions. In addition to her work on macrophages, Dr. Merad is known for her work on dendritic cells, which control adaptive immunity. She identified a new subset of dendritic cells, now considered a key antiviral and antitumor immunity target.

Dr. Merad leads the Precision Immunology Institute at the Icahn School of Medicine (PrIISM) and is the founding chair of the Department of Immunology and Immunotherapy (DII). Dr. Merad has authored more than 300 primary papers and reviews in high-profile journals. Her work has been cited several thousand times.  She is an elected member of the American Society of Clinical Investigation and the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. She is the President of the International Union of Immunological Societies (IUIS). She is an elected member of the National Academy of Sciences and National Academy of medicine and a fellow of the Academy of the American Association of Cancer Research Academy (AACR) and a fellow of the ImmunoOncology academy.